Related Experiment Video
Updated: Feb 21, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.5K
Biologics in pediatric psoriasis - efficacy and safety
1a Department of Dermatology, Venereology, and Leprology , Postgraduate Institute of Medical Education and Research , Chandigarh , India.
Expert Opinion on Drug Safety
|October 13, 2017
Summary
Biologics are effective for severe childhood psoriasis, but more long-term safety data is needed. Dermatologists should carefully consider potential adverse effects before prescribing these treatments for pediatric psoriasis.
Area of Science:
- Dermatology
- Pediatrics
- Immunology
Background:
- Childhood psoriasis presents unique management challenges.
- Biologic agents are increasingly used for severe pediatric psoriasis despite limited long-term safety data.
Purpose of the Study:
- To review the current evidence on the efficacy and safety of biologic agents in treating pediatric psoriasis.
- To highlight the need for further research into the long-term outcomes of these treatments in children.
Main Methods:
- An extensive literature search was conducted using PubMed with specific keywords related to biologics and pediatric psoriasis.
- Relevant articles published between 2000 and September 2017 were screened, including clinical trials, reviews, and case reports.
- A total of 427 articles were screened, with 41 selected for final analysis.
Main Results:
- Available literature suggests biologic agents, including anti-tumor necrosis factor (TNF)-α and anti-IL-12/23 agents, are effective for severe pediatric psoriasis.
- Current data indicates a generally favorable safety profile, but long-term safety data is still limited.
- Ustekinumab is one example of an anti-IL-12/23 agent showing promise.
Conclusions:
- Biologics are valuable therapeutic options for severe and recalcitrant pediatric psoriasis.
- Dermatologists must exercise caution regarding potential adverse effects.
- Continued research is crucial to establish comprehensive long-term safety profiles for biologics in children.
More Related Videos
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
346
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
346
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
298
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
298
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
269
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
269
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
350
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
350
01:28Drug Products: Biologics, Biosimilars and Interchangeables
293
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
293
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610